|
Market Cap | 17.19B | EPS (ttm) | 8.13 |
P/E | 21.22 | EPS this Y | -0.04% |
Forward P/E | 19.96 | EPS next Y | 9.49% |
PEG | 2.65 | EPS past 5Y | 10.71% |
P/S | 11.36 | EPS next 5Y | 8.00% |
P/B | - | EPS Q/Q | 13.03% |
Dividend | - | Sales Q/Q | 5.46% |
Insider Own | 0.89% | Inst Own | 93.50% |
Insider Trans | -7.30% | Inst Trans | -2.24% |
Short Float | 1.76% | Earnings | Apr 25/a |
Analyst Recom | 2.60 | Target Price | 204.33 |
Avg Volume | 696.53K | 52W Range | 167.04 - 229.72 |
|
|
|
VeriSign, Inc. provides domain name registry services and Internet infrastructure, which enables Internet navigation for many of the world's most recognized domain names. It enables the security, stability, and resiliency of key Internet infrastructure and services, including providing root zone maintainer services. The company was founded by D. James Bidzos in 1995, and is headquartered in Reston, VA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
McPherson Danny R | EVP - Engineering & CSO | May 17 '24 | Sale | 170.14 | 1,200 | 204,168 | 29,181 | May 20 04:37 PM | Buchalter Yehuda Ari | Director | May 10 '24 | Sale | 170.01 | 734 | 124,791 | 2,927 | May 13 04:40 PM | Buchalter Yehuda Ari | Director | May 09 '24 | Sale | 170.01 | 866 | 147,232 | 3,661 | May 13 04:40 PM | Buchalter Yehuda Ari | Director | May 07 '24 | Sale | 170.00 | 1 | 170 | 4,527 | May 09 04:43 PM | Indelicarto Thomas C | EVP, Gen Counsel & Secretary | Apr 11 '24 | Sale | 190.00 | 614 | 116,660 | 41,955 | Apr 12 04:32 PM |
|
|
|
|
Market Cap | 324.32M | EPS (ttm) | 1.18 |
P/E | 11.54 | EPS this Y | -55.03% |
Forward P/E | 15.47 | EPS next Y | 54.15% |
PEG | 2.31 | EPS past 5Y | 29.16% |
P/S | 1.17 | EPS next 5Y | 5.00% |
P/B | 1.68 | EPS Q/Q | -5.30% |
Dividend | - | Sales Q/Q | 3.81% |
Insider Own | 2.91% | Inst Own | 89.61% |
Insider Trans | -4.11% | Inst Trans | -1.74% |
Short Float | 5.79% | Earnings | May 06/a |
Analyst Recom | 1.00 | Target Price | 20.67 |
Avg Volume | 297.98K | 52W Range | 9.69 - 26.11 |
|
|
|
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Birkemeyer Elaine M. | Chief Financial Officer | May 16 '24 | Sale | 13.68 | 3,041 | 41,590 | 61,295 | May 20 04:36 PM | BURKE WILLIAM W | Director | May 08 '24 | Sale | 14.06 | 2,500 | 35,150 | 25,273 | May 10 04:24 PM | Burns Kristie | Sr. VP Mktg & Clinical Affairs | May 06 '24 | Sale | 14.37 | 815 | 11,713 | 62,574 | May 08 05:23 PM | REUVERS DANIEL L. | President and CEO | Feb 29 '24 | Sale | 15.25 | 1,396 | 21,289 | 238,027 | Feb 29 08:42 PM | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 29 '24 | Sale | 15.25 | 243 | 3,706 | 63,389 | Feb 29 08:43 PM |
|
|
|
|
Market Cap | 2.07B | EPS (ttm) | -2.87 |
P/E | - | EPS this Y | 10.56% |
Forward P/E | - | EPS next Y | 24.45% |
PEG | - | EPS past 5Y | -9.09% |
P/S | - | EPS next 5Y | 41.70% |
P/B | 4.69 | EPS Q/Q | 9.66% |
Dividend | - | Sales Q/Q | - |
Insider Own | 7.21% | Inst Own | 99.64% |
Insider Trans | -6.23% | Inst Trans | 5.52% |
Short Float | 11.68% | Earnings | May 06/a |
Analyst Recom | 1.14 | Target Price | 49.08 |
Avg Volume | 696.46K | 52W Range | 14.89 - 32.53 |
|
|
|
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shah Gaurav | CEO | May 16 '24 | Sale | 23.35 | 9,790 | 228,596 | 728,069 | May 20 04:33 PM | Patel Kinnari | See Remarks | May 16 '24 | Sale | 23.35 | 4,046 | 94,474 | 400,972 | May 20 04:26 PM | Militello John | See Remarks | May 16 '24 | Sale | 23.35 | 1,079 | 25,195 | 53,327 | May 20 04:36 PM | Wilson Martin | General Counsel | May 16 '24 | Sale | 23.35 | 1,048 | 24,471 | 65,762 | May 20 04:29 PM | Patel Kinnari | See Remarks | May 14 '24 | Option Exercise | 0.00 | 9,543 | 0 | 301,824 | May 20 04:26 PM |
|
|
| |
|
Market Cap | 1.78B | EPS (ttm) | 1.51 |
P/E | 52.60 | EPS this Y | 32.28% |
Forward P/E | 40.84 | EPS next Y | 9.66% |
PEG | 8.77 | EPS past 5Y | 3.45% |
P/S | 8.92 | EPS next 5Y | 6.00% |
P/B | 5.78 | EPS Q/Q | 61.54% |
Dividend | 0.81% | Sales Q/Q | 13.60% |
Insider Own | 9.77% | Inst Own | 90.72% |
Insider Trans | -16.69% | Inst Trans | -1.43% |
Short Float | 4.32% | Earnings | May 02/a |
Analyst Recom | 1.50 | Target Price | 78.57 |
Avg Volume | 138.66K | 52W Range | 44.27 - 79.19 |
|
|
|
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Ross Bridget A | Director | May 16 '24 | Option Exercise | 30.00 | 5,500 | 165,000 | 7,778 | May 20 04:35 PM | Ross Bridget A | Director | May 16 '24 | Sale | 77.99 | 5,500 | 428,945 | 2,278 | May 20 04:35 PM | LeMaitre George W | Chairman and CEO | May 14 '24 | Sale | 76.80 | 40,968 | 3,146,371 | 1,998,334 | May 15 04:11 PM | LeMaitre George W | Chairman and CEO | May 13 '24 | Sale | 76.42 | 35,826 | 2,737,687 | 2,043,302 | May 15 04:11 PM | LeMaitre George W | Chairman and CEO | May 08 '24 | Sale | 75.30 | 8,000 | 602,427 | 2,079,128 | May 08 04:51 PM |
|
|
|
|
Market Cap | 589.68M | EPS (ttm) | -0.74 |
P/E | - | EPS this Y | -64.66% |
Forward P/E | - | EPS next Y | -31.81% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 2.20 | EPS Q/Q | 50.98% |
Dividend | - | Sales Q/Q | - |
Insider Own | 63.11% | Inst Own | 39.80% |
Insider Trans | -0.29% | Inst Trans | - |
Short Float | 13.58% | Earnings | May 15/b |
Analyst Recom | 2.00 | Target Price | 13.50 |
Avg Volume | 150.41K | 52W Range | 4.40 - 14.58 |
|
|
|
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dittman Jennifer | Chief Development Oper Officer | May 16 '24 | Sale | 14.04 | 23,578 | 331,066 | 0 | May 20 04:33 PM | Holles Natalie C. | CEO | May 09 '24 | Option Exercise | 4.20 | 20,222 | 84,932 | 1,239,058 | May 10 04:04 PM | Holles Natalie C. | CEO | May 09 '24 | Sale | 12.18 | 20,222 | 246,300 | 1,218,836 | May 10 04:04 PM | Holles Natalie C. | CEO | Apr 11 '24 | Option Exercise | 4.20 | 13,558 | 56,944 | 1,232,394 | Apr 15 04:14 PM | Holles Natalie C. | CEO | Apr 11 '24 | Sale | 12.19 | 13,558 | 165,214 | 1,218,836 | Apr 15 04:14 PM |
|
|
| |
|
Market Cap | 7.66B | EPS (ttm) | 0.96 |
P/E | 185.76 | EPS this Y | 340.83% |
Forward P/E | 72.48 | EPS next Y | 58.76% |
PEG | 5.42 | EPS past 5Y | - |
P/S | 13.14 | EPS next 5Y | 34.30% |
P/B | 10.75 | EPS Q/Q | 995.13% |
Dividend | - | Sales Q/Q | 44.87% |
Insider Own | 15.45% | Inst Own | 80.14% |
Insider Trans | -4.62% | Inst Trans | -0.10% |
Short Float | 8.42% | Earnings | May 08/a |
Analyst Recom | 2.12 | Target Price | 252.65 |
Avg Volume | 911.77K | 52W Range | 121.89 - 251.30 |
|
|
|
Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Skaruppa Matthew | Chief Financial Officer | May 17 '24 | Sale | 177.29 | 2,698 | 478,332 | 86,709 | May 20 04:32 PM | Glance Natalie | Chief Engineering Officer | May 06 '24 | Sale | 247.82 | 1,500 | 371,735 | 123,005 | May 07 04:19 PM | Skaruppa Matthew | Chief Financial Officer | May 01 '24 | Option Exercise | 14.42 | 8,000 | 115,360 | 72,523 | May 03 07:38 PM | von Ahn Luis | President & CEO, Co-Founder | May 01 '24 | Sale | 223.51 | 12,000 | 2,682,139 | 0 | May 03 07:37 PM | Hacker Severin | Chief Tech Officer, Co-Founder | May 01 '24 | Sale | 223.47 | 10,000 | 2,234,653 | 0 | May 03 07:39 PM |
|
|
|
|
Market Cap | 23.00B | EPS (ttm) | 3.81 |
P/E | 61.13 | EPS this Y | 4.21% |
Forward P/E | 23.13 | EPS next Y | 9.37% |
PEG | 6.11 | EPS past 5Y | 1.36% |
P/S | 4.23 | EPS next 5Y | 10.00% |
P/B | 3.58 | EPS Q/Q | -100.74% |
Dividend | 0.96% | Sales Q/Q | 2.49% |
Insider Own | 0.32% | Inst Own | 97.91% |
Insider Trans | -12.89% | Inst Trans | 0.33% |
Short Float | 2.41% | Earnings | May 08/a |
Analyst Recom | 2.00 | Target Price | 243.00 |
Avg Volume | 510.94K | 52W Range | 195.47 - 254.00 |
|
|
May-20-24 04:36PM
|
Steris Insider Sold Shares Worth $267,313, According to a Recent SEC Filing
(MT Newswires) |
May-17-24 04:37PM
|
Steris Insider Sold Shares Worth $7,532,366, According to a Recent SEC Filing
(MT Newswires) |
May-16-24 04:37PM
|
Steris Insider Sold Shares Worth $476,093, According to a Recent SEC Filing
(MT Newswires) |
May-15-24 07:02PM
|
Insider Sale: SVP and President, Healthcare Cary Majors Sells Shares of Steris PLC (STE)
(GuruFocus.com) |
May-13-24 11:02AM
|
Unlocking Steris (STE) International Revenues: Trends, Surprises, and Prospects
(Zacks) |
May-10-24 12:15PM
|
Steris PLC Fiscal 2024 Earnings: Surpasses Revenue Forecasts and Adjusted EPS Expectations
(GuruFocus.com) |
11:05AM
|
STERIS plc (NYSE:STE) Q4 2024 Earnings Call Transcript
(Insider Monkey) |
08:05AM
|
Wolfe Research Adjusts Price Target on STERIS to $240 From $235
(MT Newswires) |
07:16AM
|
Piper Sandler Adjusts Price Target on STERIS to $225 From $220
(MT Newswires) |
06:07AM
|
KeyBanc Adjusts Price Target on STERIS to $255 From $253
(MT Newswires) |
|
STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Tamaro Renato | V.P. & Corporate Treasurer | May 16 '24 | Option Exercise | 114.22 | 1,154 | 131,810 | 7,831 | May 20 04:31 PM | Tamaro Renato | V.P. & Corporate Treasurer | May 16 '24 | Sale | 231.64 | 1,154 | 267,313 | 6,677 | May 20 04:31 PM | TOKICH MICHAEL J | Sr. Vice Pres., CFO | May 15 '24 | Option Exercise | 77.07 | 32,000 | 2,466,240 | 74,464 | May 17 04:31 PM | FELDMANN CYNTHIA L | Director | May 15 '24 | Option Exercise | 86.23 | 2,000 | 172,460 | 2,705 | May 17 04:33 PM | TOKICH MICHAEL J | Sr. Vice Pres., CFO | May 15 '24 | Sale | 235.39 | 32,000 | 7,532,366 | 42,464 | May 17 04:31 PM |
|
|
| |
|
Market Cap | 278.54B | EPS (ttm) | 4.21 |
P/E | 68.27 | EPS this Y | 19.16% |
Forward P/E | 25.93 | EPS next Y | 13.04% |
PEG | 4.21 | EPS past 5Y | 24.06% |
P/S | 7.99 | EPS next 5Y | 16.22% |
P/B | 4.67 | EPS Q/Q | 1576.91% |
Dividend | 0.12% | Sales Q/Q | 10.77% |
Insider Own | 3.06% | Inst Own | 82.47% |
Insider Trans | -10.16% | Inst Trans | -0.97% |
Short Float | 0.88% | Earnings | May 29/a |
Analyst Recom | 1.66 | Target Price | 336.93 |
Avg Volume | 5.58M | 52W Range | 193.68 - 318.71 |
|
|
|
Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Benioff Marc | Chair and CEO | May 17 '24 | Sale | 286.20 | 15,000 | 4,292,953 | 12,527,327 | May 20 04:31 PM | Benioff Marc | Chair and CEO | May 16 '24 | Sale | 286.44 | 15,000 | 4,296,588 | 12,542,327 | May 17 04:21 PM | Millham Brian | President and COO | May 15 '24 | Option Exercise | 218.21 | 2,106 | 459,550 | 2,106 | May 16 04:53 PM | Benioff Marc | Chair and CEO | May 15 '24 | Sale | 284.73 | 15,000 | 4,270,881 | 12,557,327 | May 16 04:45 PM | Millham Brian | President and COO | May 15 '24 | Sale | 280.00 | 2,106 | 589,680 | 0 | May 16 04:53 PM |
|
|
|
|
Market Cap | 12.19B | EPS (ttm) | 21.15 |
P/E | 12.99 | EPS this Y | 24.97% |
Forward P/E | 10.20 | EPS next Y | 8.75% |
PEG | 1.34 | EPS past 5Y | 8.15% |
P/S | 4.88 | EPS next 5Y | 9.70% |
P/B | 2.27 | EPS Q/Q | 27.02% |
Dividend | - | Sales Q/Q | 33.70% |
Insider Own | 7.84% | Inst Own | 102.43% |
Insider Trans | -13.92% | Inst Trans | 1.04% |
Short Float | 9.34% | Earnings | May 01/b |
Analyst Recom | 1.59 | Target Price | 298.16 |
Avg Volume | 532.89K | 52W Range | 204.44 - 275.00 |
|
|
May-20-24 01:34PM
|
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
(InvestorPlace) |
May-16-24 07:01PM
|
Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR)
(GuruFocus.com) |
07:01PM
|
Insider Sale: CFO and Treasurer James Edgemond Sells 40,160 Shares of United Therapeutics Corp ...
(GuruFocus.com) |
May-15-24 02:05AM
|
Q1 2024 Liquidia Corp Earnings Call
(Thomson Reuters StreetEvents) |
May-14-24 04:39PM
|
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing
(MT Newswires) |
May-10-24 04:41PM
|
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing
(MT Newswires) |
May-09-24 11:47AM
|
MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript
(Insider Monkey) |
May-08-24 05:15PM
|
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing
(MT Newswires) |
09:50AM
|
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
(Zacks) |
May-07-24 05:00PM
|
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing
(MT Newswires) |
|
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ROTHBLATT MARTINE A | Director | May 17 '24 | Option Exercise | 129.49 | 3,600 | 466,164 | 3,730 | May 20 04:30 PM | ROTHBLATT MARTINE A | Director | May 17 '24 | Sale | 273.27 | 3,600 | 983,765 | 130 | May 20 04:30 PM | ROTHBLATT MARTINE A | Director | May 16 '24 | Option Exercise | 129.49 | 3,600 | 466,164 | 3,730 | May 20 04:30 PM | ROTHBLATT MARTINE A | Director | May 16 '24 | Sale | 272.37 | 3,600 | 980,534 | 130 | May 20 04:30 PM | EDGEMOND JAMES | CFO AND TREASURER | May 15 '24 | Option Exercise | 163.30 | 40,160 | 6,558,128 | 26,578 | May 16 04:30 PM |
|
|
|
|
Market Cap | 7.38B | EPS (ttm) | 0.88 |
P/E | 115.80 | EPS this Y | -5.53% |
Forward P/E | 31.23 | EPS next Y | 28.53% |
PEG | 7.72 | EPS past 5Y | - |
P/S | 11.58 | EPS next 5Y | 15.00% |
P/B | 7.06 | EPS Q/Q | -43.33% |
Dividend | - | Sales Q/Q | 6.98% |
Insider Own | 21.03% | Inst Own | 84.27% |
Insider Trans | -11.47% | Inst Trans | 4.81% |
Short Float | 7.75% | Earnings | May 02/b |
Analyst Recom | 1.79 | Target Price | 111.92 |
Avg Volume | 543.51K | 52W Range | 56.60 - 107.00 |
|
|
May-20-24 07:00PM
|
Insider Sale: Director Charles Bland Sells 2,500 Shares of MACOM Technology Solutions Holdings ...
(GuruFocus.com) |
04:31PM
|
Macom Technology Solutions Holdings Insider Sold Shares Worth $255,966, According to a Recent SEC Filing
(MT Newswires) |
May-17-24 04:46PM
|
Macom Technology Solutions Holdings Insider Sold Shares Worth $23,904,496, According to a Recent SEC Filing
(MT Newswires) |
May-13-24 04:54PM
|
Macom Technology Solutions Holdings Insider Sold Shares Worth $3,312,421, According to a Recent SEC Filing
(MT Newswires) |
09:46AM
|
Jefferies Assumes MACOM Technology Solutions at Buy, Adjusts Price Target to $135 From $100
(MT Newswires) |
May-10-24 05:42PM
|
Macom Technology Solutions Holdings Insider Sold Shares Worth $718,564, According to a Recent SEC Filing
(MT Newswires) |
May-09-24 07:01PM
|
Insider Sale: Director Geoffrey Ribar Sells Shares of MACOM Technology Solutions Holdings Inc (MTSI)
(GuruFocus.com) |
07:00PM
|
Insider Sale: Senior VP and CFO John Kober Sells 13,666 Shares of MACOM Technology Solutions ...
(GuruFocus.com) |
05:43PM
|
Macom Technology Solutions Holdings Insider Sold Shares Worth $8,803,523, According to a Recent SEC Filing
(MT Newswires) |
May-08-24 03:06AM
|
Himax (HIMX) Reports Q1: Everything You Need To Know Ahead Of Earnings
(StockStory) |
|
MACOM Technology Solutions Holdings, Inc. engages in designing, developing, manufacturing, and marketing semiconductors and modules. The firm is involved in the provision of products for telecommunications (Telecom), industrial and defense (I&D), and data center industries. The company was founded on March 25, 2009 and is headquartered in Lowell, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
OCAMPO SUSAN | Director | May 16 '24 | Sale | 102.98 | 82,361 | 8,481,649 | 7,489,804 | May 17 04:43 PM | BLAND CHARLES R | Director | May 16 '24 | Sale | 102.39 | 2,500 | 255,966 | 26,439 | May 20 04:29 PM | OCAMPO SUSAN | Director | May 15 '24 | Sale | 102.82 | 150,000 | 15,422,847 | 7,572,165 | May 17 04:43 PM | OCAMPO SUSAN | Director | May 14 '24 | Sale | 103.04 | 85,874 | 8,848,457 | 7,722,165 | May 15 04:16 PM | OCAMPO SUSAN | Director | May 13 '24 | Sale | 103.21 | 61,765 | 6,374,766 | 7,808,039 | May 15 04:16 PM |
|
|
|